Artiva Biotherapeutics, Inc.
ARTVNASDAQHealthcare● Active
$6.80
$-0.05(-0.73%)
Market Cap$168073376
P/E Ratio—
52W High$14.53
52W Low$1.47
Artiva Biotherapeutics, Inc. (ARTV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ARTV · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.95
Est. -$0.88 · -8.0%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▼ Miss EPS
ARTV reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.63 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 8, 2026 | -$0.88 | -$0.95 | -8.0% | — | — | — |
| ▲ Q1 FY2026 | Mar 10, 2026 | -$0.87 | -$0.84 | +3.5% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.92 | -$0.88 | +4.3% | — | — | — |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.84 | -$0.87 | -3.6% | — | — | — |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.68 | -$0.83 | -22.1% | — | — | — |
| ▲ Q1 FY2025 | Mar 25, 2025 | -$0.71 | -$0.66 | +7.0% | — | — | — |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.68 | -$0.92 | -35.3% | — | — | — |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.63
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Miss
EPS Actual
-$0.95
EPS Est.
-$0.88
EPS Surpr.
-8.0%
Revenue
—
Q1 FY2026
Mar 10, 2026Beat
EPS Actual
-$0.84
EPS Est.
-$0.87
EPS Surpr.
+3.5%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.88
EPS Est.
-$0.92
EPS Surpr.
+4.3%
Revenue
—
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$0.87
EPS Est.
-$0.84
EPS Surpr.
-3.6%
Revenue
—
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.83
EPS Est.
-$0.68
EPS Surpr.
-22.1%
Revenue
—
Q1 FY2025
Mar 25, 2025Beat
EPS Actual
-$0.66
EPS Est.
-$0.71
EPS Surpr.
+7.0%
Revenue
—
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.92
EPS Est.
-$0.68
EPS Surpr.
-35.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $0.14 | $0.14 | $0.14 | 1 |
| Q3 FY2030 | $-0.06 | $-0.06 | $-0.06 | 1 |
| Q2 FY2030 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q1 FY2030 | $-0.50 | $-0.50 | $-0.50 | 1 |
| Q4 FY2029 | $-0.65 | $-0.65 | $-0.65 | 1 |
| Q3 FY2029 | $-0.75 | $-0.75 | $-0.75 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2030 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2030 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2030 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2030 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2029 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 8, 2026 | -8.0% | $12.52 | $10.89 | -13.02% |
| ▲ Q1 FY2026 | Mar 10, 2026 | +3.5% | $5.71 | $6.08 | +6.48% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +4.3% | $3.59 | $3.98 | +10.86% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -3.6% | $3.08 | $2.87 | -6.82% |
| ▼ Q2 FY2025 | May 8, 2025 | -22.1% | $2.10 | $2.18 | +3.81% |
| ▲ Q1 FY2025 | Mar 25, 2025 | +7.0% | $3.91 | $3.99 | +2.05% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -35.3% | $13.38 | $13.07 | -2.32% |
| ▼ Q3 FY2024 | Aug 29, 2024 | -400.0% | $10.93 | $11.30 | +3.39% |
Q2 FY2026-13.02%
Report Date
May 8, 2026
EPS Beat/Miss
-8.0%
Price Before
$12.52
Price After
$10.89
Q1 FY2026+6.48%
Report Date
Mar 10, 2026
EPS Beat/Miss
+3.5%
Price Before
$5.71
Price After
$6.08
Q4 FY2025+10.86%
Report Date
Nov 12, 2025
EPS Beat/Miss
+4.3%
Price Before
$3.59
Price After
$3.98
Q3 FY2025-6.82%
Report Date
Aug 6, 2025
EPS Beat/Miss
-3.6%
Price Before
$3.08
Price After
$2.87
Q2 FY2025+3.81%
Report Date
May 8, 2025
EPS Beat/Miss
-22.1%
Price Before
$2.10
Price After
$2.18
Q1 FY2025+2.05%
Report Date
Mar 25, 2025
EPS Beat/Miss
+7.0%
Price Before
$3.91
Price After
$3.99
Q4 FY2024-2.32%
Report Date
Nov 12, 2024
EPS Beat/Miss
-35.3%
Price Before
$13.38
Price After
$13.07
Q3 FY2024+3.39%
Report Date
Aug 29, 2024
EPS Beat/Miss
-400.0%
Price Before
$10.93
Price After
$11.30
Avg Beat Reaction+6.46%
Avg Miss Reaction-2.99%
Beat Rate3 / 8 quarters
Largest Move-13.02% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ARTV ends December
Artiva Biotherapeutics, Inc. (ARTV) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.95 — missing the analyst consensus of $-0.88 by -8.0%. The next ARTV earnings date is expected around September 1, 2026.
Each quarter, investors track ARTV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ARTV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ARTV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ARTV earnings · 5 questionsArtiva Biotherapeutics, Inc.'s next earnings report is expected around September 1, 2026. ARTV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ARTV historically reports after market close (AMC).
ARTV earnings datewhen is ARTV earningsARTV next earnings datewhen does ARTV report earningsARTV earnings calendar
▸ Source: FMP · Artiva Biotherapeutics, Inc. SEC filings · US GAAP · Artiva Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026